$0.9800
0.0050.51%
Last update: Oct 23, 6:41 PM
Cellectis SA (CLLS) Stock Price, Quote, News & History
CLLSNASDAQ
Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Cellectis has a consensus price target of $6.47.
The stock price for Cellectis (NASDAQ: CLLS) is $0.929 last updated October 23, 2026 at 6:41 PM EDT.
There are no upcoming dividends for Cellectis.
Cellectis does not have any upcoming earnings scheduled.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the...
